Back to today’s briefing

Story perspectives

Harvard Study: Statins Slash Liver Cancer Risk by 33%

3/28/2025

41 8

Summary

Story summary

A groundbreaking study from Harvard Medical School reveals that statins can dramatically reduce the risk of liver cancer in those with chronic liver disease. Analyzing 16,501 participants, researchers found that statin users experienced a 33% lower risk of hepatocellular carcinoma and a 22% decrease in severe liver complications, with lipophilic statins offering the most protection.

1 of 1

Story summary

A groundbreaking study from Harvard Medical School reveals that statins can dramatically reduce the risk of liver cancer in those with chronic liver disease. Analyzing 16,501 participants, researchers found that statin users experienced a 33% lower risk of hepatocellular carcinoma and a 22% decrease in severe liver complications, with lipophilic statins offering the most protection.